Biosero Company Profile

Background

Founded in 2003, Biosero, Inc. specializes in developing laboratory automation solutions that enable researchers to orchestrate scientific discoveries. The company's mission is to make laboratory automation accessible, scalable, and adaptable to the evolving needs of scientific research. Biosero's flagship product, the Green Button Go® software suite, integrates diverse laboratory instruments and workflows, enhancing efficiency and productivity across life sciences, biotechnology, pharmaceutical, and diagnostic research sectors.

Key Strategic Focus

Biosero focuses on delivering flexible and robust automation solutions tailored to the dynamic nature of scientific research. The Green Button Go® software suite serves as the core of their offerings, providing seamless integration of laboratory instruments and workflows. This platform supports a wide range of applications, including genomics, cell biology, proteomics, compound management, and clinical diagnostics. By enabling end-to-end laboratory management, Biosero aims to accelerate research processes and improve decision-making capabilities for its clients.

Financials and Funding

In December 2021, Biosero was acquired by BICO Group AB for an enterprise value of $165 million. The acquisition comprised approximately 63% cash, 21% in newly issued BICO shares, and 16% through an earnout component over three years. Post-acquisition, BICO committed to investing up to $20 million over three years to accelerate Biosero's commercial expansion and product development. In 2021, Biosero reported revenues of approximately $26 million with an EBITDA margin exceeding 25%.

Technological Platform and Innovation

Biosero's Green Button Go® software suite is a proprietary platform designed to automate and orchestrate laboratory workflows. The suite includes the Green Button Go® Scheduler, which allows scientists to automate workflows ranging from single workstations to operations spanning multiple labs. The software's flexibility and scalability are enhanced by numerous extensions and an intuitive control interface, making it easily customizable for various laboratory needs. In May 2022, Biosero was awarded a patent for its Multipath Scheduler technology, which enables dynamic planning and optimization of complex labware transportation scenarios across different modes of transportation, such as robotic arms, tracks, conveyors, and autonomous mobile robots.

Leadership Team

Ryan Bernhardt, Chief Executive Officer: Appointed CEO in September 2023, Bernhardt previously served as Biosero's Chief Commercial Officer.

Michelle Talarico, Chief Financial Officer: Oversees financial operations, bringing extensive experience in financial management within the technology sector.

Daniel Schumann, Chief Operations Officer: Joined Biosero in April 2024, responsible for overseeing all operational functions, including supply chain, procurement, integrations, engineering, project management, quality, and IT.

Rob Harkness, PhD, Chief Technology Officer: Promoted to CTO in August 2023, Dr. Harkness previously served as the company's Managing Director for the European Union and United Kingdom.

Leadership Changes

In September 2023, Ryan Bernhardt was promoted to Chief Executive Officer, succeeding founding CEO Tom Gilman, who transitioned out of the role by the end of that month. In August 2023, Rob Harkness, PhD, was promoted to Chief Technology Officer. In March 2024, Daniel Schumann was appointed as Chief Operations Officer, starting his role in April 2024.

Competitor Profile

Market Insights and Dynamics

The laboratory automation market is experiencing significant growth, driven by the increasing demand for high-throughput screening, precision medicine, and efficient laboratory workflows. Advancements in artificial intelligence and machine learning are further propelling the adoption of automated solutions in research and clinical laboratories.

Competitor Analysis

Biosero operates in a competitive landscape with several key players:

HighRes Biosolutions: Specializes in designing and building laboratory automation systems, offering integrated platforms for various applications.

Opentrons: Provides affordable and user-friendly robotic platforms for laboratory automation, focusing on accessibility and open-source solutions.

Gilson: Offers a range of liquid handling solutions and laboratory instruments, emphasizing precision and reliability in laboratory workflows.

These competitors focus on integrating hardware and software solutions to streamline laboratory processes, enhance reproducibility, and increase throughput.

Strategic Collaborations and Partnerships

Biosero has established several strategic collaborations to enhance its market position and innovation capacity:

BD (Becton, Dickinson and Company): In January 2025, Biosero and BD announced a framework collaboration to enable robotic arm integration with BD flow cytometry instruments, aiming to accelerate drug discovery and development.

BioNex Solutions: In October 2024, Biosero partnered with BioNex to deliver an enhanced experience for customers using the Hive Laboratory Automation platform, integrating Biosero's Green Button Go® Scheduler software.

DeepCure: In January 2023, Biosero collaborated with DeepCure to establish a fully automated, AI-powered chemistry synthesis platform, combining DeepCure's AI engine with Biosero's Green Button Go® software suite.

Operational Insights

Biosero's strategic focus on flexible and scalable automation solutions positions it competitively in the laboratory automation market. The company's emphasis on software-driven integration allows for seamless connectivity across various laboratory instruments, providing a distinct advantage over competitors that may offer more rigid or hardware-centric solutions. Biosero's commitment to innovation is demonstrated through its Acceleration Lab, which serves as a proving ground for lab automation technology, offering real-world environments for prospective customers to experience their solutions. This initiative was recognized with the 2022 Sales and Marketing Technology Award for Product of the Year.

Strategic Opportunities and Future Directions

Under the ownership of BICO Group AB, Biosero is poised for accelerated growth and expansion into new geographical markets. The planned investment of up to $20 million over three years aims to enhance Biosero's commercial presence and product development capabilities. The company's focus on integrating artificial intelligence and machine learning into its automation solutions presents opportunities to further streamline laboratory workflows and improve research outcomes. Additionally, Biosero's ongoing collaborations with industry leaders position it to address emerging challenges in drug discovery and development, reinforcing its role as a key player in the laboratory automation sector.